Table 3.
Cause of death
| Number (%) | |||||
|---|---|---|---|---|---|
| Primary disease | Secondary malignancy | Cardiovascular disease | Others | Unknown | |
| Total (N = 1424) | 1147 (80.5) | 47 (3.3) | 61 (4.3) | 108 (7.6) | 61 (4.3) |
| Time | |||||
| 1996‐2000 | 101 (99.0) | 0 (0) | 0 (0) | 0 (0) | 1 (1.0) |
| 2001‐2005 | 184 (92.0) | 2 (1.0) | 4 (2.0) | 4 (2.0) | 6 (3.0) |
| 2006‐2010 | 358 (79.7) | 15 (3.3) | 23 (5.1) | 37 (8.3) | 16 (3.6) |
| 2011‐2015 | 504 (74.9) | 30 (4.5) | 34 (5.1) | 67 (9.9) | 38 (5.6) |
| Histology | |||||
| HL (N = 165) | 134 (9.4) | 5 (0.4) | 6 (0.4) | 16 (1.1) | 4 (0.3) |
| NHL (N = 1259) | 1013 (71.7) | 42 (2.9) | 55 (3.9) | 92 (6.5) | 57 (4.0) |
| LBL (N = 60) | 48 (3.4) | 1 (0.1) | 4 (0.3) | 4 (0.3) | 3 (0.2) |
| Mature BCL (N = 933) | 744 (52.3) | 34 (2.4) | 40 (2.8) | 71 (5.0) | 44 (3.1) |
| FL (N = 94) | 76 (5.3) | 3 (0.2) | 5 (0.4) | 5 (0.4) | 94 (6.6) |
| SLL (N = 25) | 18 (1.3) | 2 (0.1) | 2 (0.1) | 2 (0.1) | 1 (0.1) |
| MZL (N = 62) | 52 (3.7) | 2 (0.1) | 3 (0.2) | 2 (0.1) | 3 (0.2) |
| BL (N = 10) | 6 (0.4) | 0 (0) | 2 (0.1) | 1 (0.1) | 1 (0.1) |
| DLBCL (N = 618) | 487 (34.2) | 25 (1.8) | 24 (1.7) | 52 (3.7) | 30 (2.1) |
| MCL (N = 39) | 28 (2.0) | 1 (0.4) | 4 (0.3) | 4 (0.3) | 2 (0.1) |
| Others (N = 85) | 77 (5.4) | 1 (0.1) | 0 (0) | 5 (0.4) | 2 (0.1) |
| PTCL (N = 266) | 221 (15.5) | 7 (0.5) | 11 (0.8) | 17 (1.2) | 10 (0.7) |
| ALK+ALCL (N = 16) | 15 (1.1) | 0 (0) | 0 (0) | 1 (0.1) | 0 (0) |
| ALK−ALCL (N = 11) | 6 (0.4) | 1 (0.1) | 1 (0.1) | 3 (0.2) | 0 (0) |
| NKTCL (N = 110) | 85 (6.0) | 3 (0.2) | 10 (0.7) | 8 (0.6) | 4 (0.3) |
| AITL (N = 30) | 24 (1.7) | 1 (0.1) | 0 (0) | 2 (0.1) | 3 (0.2) |
| PTCL NOS (N = 26) | 24 (1.7) | 1 (0.1) | 0 (0) | 1 (0.1) | 0 (0) |
| Others (N = 73) | 67 (4.7) | 1 (0.1) | 0 (0) | 2 (0.1) | 3 (0.2) |
AITL, angioimmunoblastic T‐cell lymphoma; ALK+ALCL, ALK+ anaplastic large cell lymphoma; ALK−ALCL, ALK− anaplastic large cell lymphoma; BCL, B‐cell lymphoma; BL, Burkitt lymphoma; DLBCL, diffuse large B‐cell lymphoma; FL, follicular lymphoma; HL, Hodgkin lymphoma; LBL: lymphoblastic lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non–Hodgkin lymphoma; NKTCL, natural killer/T‐cell lymphoma; PTCL: peripheral T‐cell lymphomas; PTCL NOS, peripheral T‐cell lymphoma not otherwise specified; SLL, small lymphocytic lymphoma/chronic lymphocytic leukemia